QURE ▲ +5.1% - uniQure N.V. $QURE - uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington’s Disease uniQure shares rose 5.1% following the company's announcement that it has submitted a Biologics License Application to the FDA for AMT-130, its gene therapy candidate for Huntington's disease. The BLA submission represents a key regulatory milestone for the treatment, which uniQure is positioning as a potential therapy for this serious neurodegenerative condition. 02-SEP-2026 07:05 AM ET